ATE136215T1 - Zusammensetzung zur reparatur und vorbeugung fibrotischer schäden - Google Patents

Zusammensetzung zur reparatur und vorbeugung fibrotischer schäden

Info

Publication number
ATE136215T1
ATE136215T1 AT90903464T AT90903464T ATE136215T1 AT E136215 T1 ATE136215 T1 AT E136215T1 AT 90903464 T AT90903464 T AT 90903464T AT 90903464 T AT90903464 T AT 90903464T AT E136215 T1 ATE136215 T1 AT E136215T1
Authority
AT
Austria
Prior art keywords
prevention
composition
repair
fibrotic
fibrotic damage
Prior art date
Application number
AT90903464T
Other languages
German (de)
English (en)
Inventor
Solomon B Margolin
Original Assignee
Solomon B Margolin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solomon B Margolin filed Critical Solomon B Margolin
Application granted granted Critical
Publication of ATE136215T1 publication Critical patent/ATE136215T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
AT90903464T 1989-02-15 1990-01-26 Zusammensetzung zur reparatur und vorbeugung fibrotischer schäden ATE136215T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1035436A JPH02215719A (ja) 1989-02-15 1989-02-15 線維化病変組織の修復並びに線維化病変の阻止剤

Publications (1)

Publication Number Publication Date
ATE136215T1 true ATE136215T1 (de) 1996-04-15

Family

ID=12441800

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90903464T ATE136215T1 (de) 1989-02-15 1990-01-26 Zusammensetzung zur reparatur und vorbeugung fibrotischer schäden

Country Status (9)

Country Link
EP (3) EP0458861B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH02215719A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE136215T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU633541B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2010017C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE69034143T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0458861T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2163389T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1990009176A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
JPH08510251A (ja) * 1993-05-07 1996-10-29 ビー マーゴリン、ソロモン 線維症の病変の修復と予防のための組成物および方法
ATE265851T1 (de) * 1995-03-03 2004-05-15 Solomon B Margolin Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden
JP2002526447A (ja) 1998-09-18 2002-08-20 メファ・アクチェンゲゼルシャフト アルキルフェニルピリドンの局所製剤
ATE452637T1 (de) 2001-01-29 2010-01-15 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1- phenyl-2-(1h)-pyridon enthält
JP4542743B2 (ja) 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
WO2004073680A1 (ja) * 2003-02-21 2004-09-02 Shionogi & Co., Ltd. 液滴分散型軟膏剤
TW200501952A (en) * 2003-02-21 2005-01-16 Shionogi & Co Pirfenidone gel formulations
WO2005047256A1 (fr) 2003-11-14 2005-05-26 Shanghai Genomics, Inc. Derives de pyridone, et utilisation correspondante
CN1846699A (zh) * 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
WO2007147297A1 (en) 2006-06-15 2007-12-27 Shanghai Genomics, Inc. The use of derviate of pyridone for preventing and treating radioactive injury of lungs
MX2007006347A (es) * 2007-05-29 2009-02-18 Cell Therapy And Technology S Nuevo uso de 5-metil-1-fenil-2-(1h)-piridona para el tratamiento y prevencion de cicatrices hipertroficas, y composicion conteniendo la misma.
CN104892498A (zh) 2007-06-20 2015-09-09 奥斯拜客斯制药有限公司 作为纤维化抑制剂的取代的n-芳基吡啶酮
US20100099719A1 (en) * 2008-10-21 2010-04-22 Dierepharma, Inc. Composition and method for treating proteinuria
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) * 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US10092552B2 (en) * 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2828895A1 (en) 2011-03-08 2012-09-13 Auspex Pharamaceuticals, Inc. Substituted n-aryl pyridinones
MY168300A (en) 2011-09-14 2018-10-25 Shionogi & Co Pharmaceutical Composition for Inhalation
KR102057877B1 (ko) 2012-07-18 2019-12-20 노스 앤드 사우스 브라더 파마시 인베스트먼트 컴파니 리미티드 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도
US12226407B2 (en) 2012-07-24 2025-02-18 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
CN104725356B (zh) 2013-12-19 2017-02-22 广东东阳光药业有限公司 氮杂环衍生物及其在药物中的应用
EP3307714A1 (en) 2015-01-26 2018-04-18 Ulkar Kimya Sanayii Ve Ticaret A. S. An improved method for the synthesis and purification of pirfenidone
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
CN109223723B (zh) * 2017-07-11 2021-08-27 南京华威医药科技集团有限公司 吡非尼酮片剂及其制备方法和用途
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
MX2020005775A (es) * 2020-07-13 2022-01-14 Centro De Retina Medica Y Quirurgica S C Uso farmaceutico de pirfenidona para la reduccion de fibrosis cardiaca en pacientes con cardiomiopatia y/o esteatosis cardiaca y/o covid-19.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6816241A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1967-12-01 1969-06-03
US3721676A (en) * 1969-11-12 1973-03-20 Merck & Co Inc Certain 3-amino-2(1h)pyridones
US3644626A (en) * 1969-11-25 1972-02-22 Merck & Co Inc Novel pyridones in compositions and methods for treating inflammation pain and fever
US3655897A (en) * 1971-01-25 1972-04-11 Merck & Co Inc Anti-inflammatory agents
CA1049411A (en) * 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4052509A (en) * 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US4042699A (en) * 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
ZA757570B (en) * 1974-12-09 1977-07-27 Affiliated Med Res A useful n-substituted pyridone
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤

Also Published As

Publication number Publication date
JPH02215719A (ja) 1990-08-28
DE69034143T2 (de) 2005-06-30
CA2010017C (en) 1995-09-05
ES2220612T3 (es) 2004-12-16
EP1138329B8 (en) 2006-05-17
AU633541B2 (en) 1993-02-04
EP0458861A4 (en) 1992-07-08
EP1138329A3 (en) 2002-04-17
ES2163389T3 (es) 2002-02-01
JPH0552814B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-08-06
CA2010017A1 (en) 1990-08-15
EP0383591B1 (en) 2001-11-21
EP0458861A1 (en) 1991-12-04
WO1990009176A1 (en) 1990-08-23
EP1138329A2 (en) 2001-10-04
EP1138329B1 (en) 2004-06-02
DE69034143D1 (de) 2004-07-08
DE69033863D1 (de) 2002-01-03
EP0383591A3 (en) 1992-01-15
DE69033863T2 (de) 2002-06-13
DK0458861T3 (da) 1996-08-12
AU4981290A (en) 1990-08-23
EP0458861B1 (en) 1996-04-03
EP0383591A2 (en) 1990-08-22

Similar Documents

Publication Publication Date Title
ATE136215T1 (de) Zusammensetzung zur reparatur und vorbeugung fibrotischer schäden
DK407483A (da) Antibakterielle naphthyridin-, quinolin- og benzoxazincarboxylsyrer, fremgangsmaader til deres fremstilling, deres anvendelse og mellemprodukter anvendelige ved forbindelsernes fremstilling
EP0266576A3 (en) 1-tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents
DE69132006D1 (de) Thiazolederivate als inhibitoren von aktivem sauerstoff
DE69115360D1 (de) Verfahren und Gerät zur Pflege der Aktivität einer Enzymelektrode
FI935020A7 (fi) Interleukiini-1b-proteaasi ja interleukiini-1b-proteaasin inhibiittoreita
DE59409200D1 (de) Pharmazeutisches Präparat enthaltend Glucosidase- und/oder Amylasehemmer und einen Lipasehemmer
FI913142A0 (fi) Migraenfoerhindrande alkoxipyrimidinderivat.
MX9102138A (es) Inhibidores de proteasa retroviral
EP0471756A4 (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof
EP0273689A3 (en) Derivatives of n-(2-alkyl-3-mercapto-glutaryl) alpha-amino acids and their use as collagenase inhibitors
GR1001218B (el) Μεθοδος παρασκευης αλατων κεφαλοσπορινης και ενεσιμων συνθεσεων
ATE92717T1 (de) Verfahren zur verbesserung der wirksamkeit von insektentoxinen.
KR880700673A (ko) 골손상 치료용방법 및 조성물
MX9101861A (es) Novedosos 2-sacarinilmetil ari carboxilatos utiles como inhibidores de enzima proteolitica y composiciones y metodo para usarlos
ES2095578T3 (es) Composicion para el tratamiento de mastitis y metritis.
FI911269A7 (fi) Menetelmä ja koostumus aktiivisten aineiden lisääntyneen pitoisuuden aikaansaamiseksi iholla iontoforeesin avulla
EE9600044A (et) Püranooni derivaadid kui proteaasi inhibiitorid ja viirusevastased toimeained
AT388949B (de) Fahrbare gleisbearbeitungsmaschine fuer den weichen- und kreuzungsbereich
DE59303284D1 (de) Vorrichtung zur Schadensverhinderung an Gebäuden in Bereichen von Bodenbewegungen
FI960489A7 (fi) Menetelmiä proteolyyttisen entsyymin inhibiittoreina käyttökelpoisten sakkariinijohdannaisten ja niiden välituotteiden valmistamiseksi
ATA61587A (de) Hoehenverstellbares tischgestell fuer arbeits- und werktische
MX9203685A (es) Nuevos derivados de mercaptoacetil-amida utiles como inhibidores de encefalinasa y ace.
SE8704463D0 (sv) Sett att bearbeta arbetsstycken i hallare samt anordning for genomforande av forfarandet
BR6401935U (pt) Carrinho de chopp ambulantes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time